Cargando…

Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?

INTRODUCTION: To evaluate the actual perceptions of hormonal contraceptives (HC) in women of reproductive age in comparison with similar concerns of postmenopausal women in relation to hormone therapy (HT). MATERIALS AND METHODS: A questionnaire-based study was conducted in a population of 370 women...

Descripción completa

Detalles Bibliográficos
Autores principales: Grandi, Giovanni, Del Savio, Maria Chiara, Boggio Sola, Valentina, Monari, Francesca, Melotti, Chiara, Facchinetti, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205098/
https://www.ncbi.nlm.nih.gov/pubmed/34124968
http://dx.doi.org/10.1080/07853890.2021.1938662
_version_ 1783708441261375488
author Grandi, Giovanni
Del Savio, Maria Chiara
Boggio Sola, Valentina
Monari, Francesca
Melotti, Chiara
Facchinetti, Fabio
author_facet Grandi, Giovanni
Del Savio, Maria Chiara
Boggio Sola, Valentina
Monari, Francesca
Melotti, Chiara
Facchinetti, Fabio
author_sort Grandi, Giovanni
collection PubMed
description INTRODUCTION: To evaluate the actual perceptions of hormonal contraceptives (HC) in women of reproductive age in comparison with similar concerns of postmenopausal women in relation to hormone therapy (HT). MATERIALS AND METHODS: A questionnaire-based study was conducted in a population of 370 women, 198 (53.5%) premenopausal and 172 (46.5%) postmenopausal. Perceptions were evaluated using specific questions and Likert scales (-5 to +5).Multivariate regression analyses were adjusted for categories of HC/HT use (never, past and current). RESULTS: The most reported adverse effect associated with hormonal treatments was venous thrombosis (1.4 ± 0.1), especially for HC use in premenopausal women (p < .0001). According to responses, hormonal treatments can increase the risk of developing venous thrombosis (OR 0.79; 95% CI 0.67–0.96, p = .004) and depression (OR 0.80; 95% CI 0.69–0.92, p = .002) more in pre-menopause, while they can increase the risk of weight gain more in post-menopause (OR 1.24: 95% CI 1.07–1.42, p = .003).The greatest oncological concern throughout life was about breast cancer (0.9 ± 0.1). There was the perception that hormonal treatments can increase the risk of developing ovarian cancer more in post-menopause (OR 1.44; 95% CI 1.19–1.75, p = .0002), while they can increase the risk of uterine cervix cancer more in pre-menopause (OR 0.74; 95% CI 0.52–0.97, p = .03). CONCLUSIONS: Our data suggest that our patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk, and, later in life, about their impact on weight gain, breast and ovarian cancer risk. KEY MESSAGES: 1. Young patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk. 2. Older patients are primarily concerned about the effects of hormonal treatments on weight gain, breast and ovarian cancer risk. 3. The greatest oncological concern throughout life was about breast cancer.
format Online
Article
Text
id pubmed-8205098
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-82050982021-06-24 Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause? Grandi, Giovanni Del Savio, Maria Chiara Boggio Sola, Valentina Monari, Francesca Melotti, Chiara Facchinetti, Fabio Ann Med Pregnancy, Childbirth & Women’s Health INTRODUCTION: To evaluate the actual perceptions of hormonal contraceptives (HC) in women of reproductive age in comparison with similar concerns of postmenopausal women in relation to hormone therapy (HT). MATERIALS AND METHODS: A questionnaire-based study was conducted in a population of 370 women, 198 (53.5%) premenopausal and 172 (46.5%) postmenopausal. Perceptions were evaluated using specific questions and Likert scales (-5 to +5).Multivariate regression analyses were adjusted for categories of HC/HT use (never, past and current). RESULTS: The most reported adverse effect associated with hormonal treatments was venous thrombosis (1.4 ± 0.1), especially for HC use in premenopausal women (p < .0001). According to responses, hormonal treatments can increase the risk of developing venous thrombosis (OR 0.79; 95% CI 0.67–0.96, p = .004) and depression (OR 0.80; 95% CI 0.69–0.92, p = .002) more in pre-menopause, while they can increase the risk of weight gain more in post-menopause (OR 1.24: 95% CI 1.07–1.42, p = .003).The greatest oncological concern throughout life was about breast cancer (0.9 ± 0.1). There was the perception that hormonal treatments can increase the risk of developing ovarian cancer more in post-menopause (OR 1.44; 95% CI 1.19–1.75, p = .0002), while they can increase the risk of uterine cervix cancer more in pre-menopause (OR 0.74; 95% CI 0.52–0.97, p = .03). CONCLUSIONS: Our data suggest that our patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk, and, later in life, about their impact on weight gain, breast and ovarian cancer risk. KEY MESSAGES: 1. Young patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk. 2. Older patients are primarily concerned about the effects of hormonal treatments on weight gain, breast and ovarian cancer risk. 3. The greatest oncological concern throughout life was about breast cancer. Taylor & Francis 2021-06-14 /pmc/articles/PMC8205098/ /pubmed/34124968 http://dx.doi.org/10.1080/07853890.2021.1938662 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pregnancy, Childbirth & Women’s Health
Grandi, Giovanni
Del Savio, Maria Chiara
Boggio Sola, Valentina
Monari, Francesca
Melotti, Chiara
Facchinetti, Fabio
Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?
title Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?
title_full Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?
title_fullStr Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?
title_full_unstemmed Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?
title_short Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?
title_sort attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?
topic Pregnancy, Childbirth & Women’s Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205098/
https://www.ncbi.nlm.nih.gov/pubmed/34124968
http://dx.doi.org/10.1080/07853890.2021.1938662
work_keys_str_mv AT grandigiovanni attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause
AT delsaviomariachiara attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause
AT boggiosolavalentina attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause
AT monarifrancesca attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause
AT melottichiara attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause
AT facchinettifabio attitudesofwomentowardsproductscontaininghormoneshormonalcontraceptivesorhormonetherapywhatchangesfrompretopostmenopause